Given the high prevalence of mood and anxiety disorders among individuals with AD, targeting both disorders may also be a key component in meeting the treatment needs of this population. There is evidence that sertraline plus naltrexone (Pettinati et al., 2010) may be effective in reducing depressive symptoms and alcohol consumption among depressed individuals with AD. In addition, there is evidence that cognitive-behavioral therapy is useful in treating the combination of depression and AD (Brown et al., 1997).
